Telo Genomics Corp Stock Fundamentals
| TELO Stock | CAD 0.12 0.01 9.09% |
Telo Genomics Corp fundamentals help investors to digest information that contributes to Telo Genomics' financial success or failures. It also enables traders to predict the movement of Telo Stock. The fundamental analysis module provides a way to measure Telo Genomics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Telo Genomics stock.
At this time, Telo Genomics' Depreciation And Amortization is fairly stable compared to the past year. Interest Expense is likely to climb to 7,065 in 2024, whereas Other Operating Expenses is likely to drop slightly above 2.3 M in 2024. Telo | Select Account or Indicator |
Telo Genomics Corp Company Return On Equity Analysis
Telo Genomics' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Telo Genomics Return On Equity | -1.69 |
Most of Telo Genomics' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Telo Genomics Corp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Telo Return On Equity Driver Correlations
Understanding the fundamental principles of building solid financial models for Telo Genomics is extremely important. It helps to project a fair market value of Telo Stock properly, considering its historical fundamentals such as Return On Equity. Since Telo Genomics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Telo Genomics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Telo Genomics' interrelated accounts and indicators.
Click cells to compare fundamentals
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Telo Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Telo Genomics Corp has a Return On Equity of -1.6942. This is 92.93% lower than that of the Biotechnology sector and 74.64% lower than that of the Health Care industry. The return on equity for all Canada stocks is notably higher than that of the company.
Telo Genomics Corp Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Telo Genomics's current stock value. Our valuation model uses many indicators to compare Telo Genomics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Telo Genomics competition to find correlations between indicators driving Telo Genomics's intrinsic value. More Info.Telo Genomics Corp is currently regarded as top stock in return on equity category among its peers. It is rated third in return on asset category among its peers . At this time, Telo Genomics' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Telo Genomics' earnings, one of the primary drivers of an investment's value.Telo Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Telo Genomics' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Telo Genomics could also be used in its relative valuation, which is a method of valuing Telo Genomics by comparing valuation metrics of similar companies.Telo Genomics is currently under evaluation in return on equity category among its peers.
Telo Genomics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Telo Genomics from analyzing Telo Genomics' financial statements. These drivers represent accounts that assess Telo Genomics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Telo Genomics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 1.7M | 7.2M | 23.4M | 21.0M | 17.7M | 13.2M | |
| Enterprise Value | 1.9M | 6.3M | 19.8M | 18.3M | 15.1M | 12.4M |
Telo Fundamentals
| Return On Equity | -1.69 | ||||
| Return On Asset | -0.87 | ||||
| Current Valuation | 6.94 M | ||||
| Shares Outstanding | 74.56 M | ||||
| Shares Owned By Insiders | 5.34 % | ||||
| Shares Owned By Institutions | 2.74 % | ||||
| Number Of Shares Shorted | 2.46 K | ||||
| Price To Book | 220.96 X | ||||
| EBITDA | (2.79 M) | ||||
| Net Income | (2.82 M) | ||||
| Cash And Equivalents | 24.25 K | ||||
| Total Debt | 32.5 K | ||||
| Current Ratio | 0.09 X | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (2.63 M) | ||||
| Short Ratio | 0.07 X | ||||
| Earnings Per Share | (0.04) X | ||||
| Beta | 1.04 | ||||
| Market Capitalization | 8.57 M | ||||
| Total Asset | 2.93 M | ||||
| Retained Earnings | (25.12 M) | ||||
| Working Capital | 2.56 M | ||||
| Net Asset | 2.93 M |
About Telo Genomics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Telo Genomics Corp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Telo Genomics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Telo Genomics Corp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | -924.8 K | -971 K | |
| Cost Of Revenue | 38.1 K | 55.4 K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Telo Stock Analysis
When running Telo Genomics' price analysis, check to measure Telo Genomics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Telo Genomics is operating at the current time. Most of Telo Genomics' value examination focuses on studying past and present price action to predict the probability of Telo Genomics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Telo Genomics' price. Additionally, you may evaluate how the addition of Telo Genomics to your portfolios can decrease your overall portfolio volatility.